Elutia Secures $15M Loan to Fund NXT-41x Launch in $1.5B Market
ELUT sits 58% above its 52-week low of $0.5.
Summary
Elutia secured a $15 million loan from Avenue Capital Group, with $10 million already closed and an additional $5 million available. The financing funds development and commercialization of NXT-41x, its antibiotic-eluting biomatrix for plastic and reconstructive surgery, targeting a $1.5 billion U.S. market. FDA clearance is anticipated in the first half of 2027. This follows a Nasdaq delisting notice on August 6 and a Q1 net loss of $7.47 million, so the capital extends runway and supports a key product launch. The loan strengthens the balance sheet and reduces near-term liquidity risk, though dilution or debt service terms are not disclosed.
At the time of this announcement, ELUT was trading at $0.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38M. The 52-week trading range was $0.50 to $2.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.